[
  {
    "ts": null,
    "headline": "Stocks to Watch Monday: Tesla, Amazon, Boeing",
    "summary": "↗️ Tesla (TSLA): The EV maker's board approved a compensation package for Chief Executive Elon Musk valued at nearly $24 billion, after earlier pay deals were struck down by a judge. Shares climbed 2% premarket.",
    "url": "https://finnhub.io/api/news?id=90de445cfd72bb32f11b53d1ac45f6b2799e9b2173aa49f5315605d058eaa9c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754306900,
      "headline": "Stocks to Watch Monday: Tesla, Amazon, Boeing",
      "id": 136197756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "↗️ Tesla (TSLA): The EV maker's board approved a compensation package for Chief Executive Elon Musk valued at nearly $24 billion, after earlier pay deals were struck down by a judge. Shares climbed 2% premarket.",
      "url": "https://finnhub.io/api/news?id=90de445cfd72bb32f11b53d1ac45f6b2799e9b2173aa49f5315605d058eaa9c4"
    }
  },
  {
    "ts": null,
    "headline": "Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics",
    "summary": "While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=fbf300e278dc6469fb1091af354558a63daba2d39b850af14085bf125543adf2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754343001,
      "headline": "Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics",
      "id": 136205905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=fbf300e278dc6469fb1091af354558a63daba2d39b850af14085bf125543adf2"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates",
    "summary": "Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=17139bcf9f0a0b0cb0f60f3faab5c5a89e07aa683f78b3286beac272f090f908",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754342103,
      "headline": "Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates",
      "id": 136205906,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=17139bcf9f0a0b0cb0f60f3faab5c5a89e07aa683f78b3286beac272f090f908"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings",
    "summary": "The biotechnology company’s stock fell in post-market trading, after saying it would not progress a next-generation pain treatment into advanced testing.",
    "url": "https://finnhub.io/api/news?id=2e9f31b42a6787ea80fc757af7e3cb10274cccf27212f1d01f529ced68a69eb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754341980,
      "headline": "Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings",
      "id": 136205907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The biotechnology company’s stock fell in post-market trading, after saying it would not progress a next-generation pain treatment into advanced testing.",
      "url": "https://finnhub.io/api/news?id=2e9f31b42a6787ea80fc757af7e3cb10274cccf27212f1d01f529ced68a69eb5"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat",
    "summary": "Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.",
    "url": "https://finnhub.io/api/news?id=a0d6b624278dc77ec6c7e77ded5401a5a6675f9b9c6985ba6ee80f8e01307998",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754339707,
      "headline": "Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat",
      "id": 136205908,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.",
      "url": "https://finnhub.io/api/news?id=a0d6b624278dc77ec6c7e77ded5401a5a6675f9b9c6985ba6ee80f8e01307998"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=0668ddb744525df961ba9522bea10ba116a8b11fa1753ea2567b71b19c0045ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754338878,
      "headline": "Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%",
      "id": 136205909,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=0668ddb744525df961ba9522bea10ba116a8b11fa1753ea2567b71b19c0045ed"
    }
  },
  {
    "ts": null,
    "headline": "Vertex: Q2 Earnings Snapshot",
    "summary": "The Boston-based company said it had net income of $3.99 per share. Earnings, adjusted for one-time gains and costs, were $4.52 per share. The results beat Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=a0e2ef697c5b5d8e2f6fcddc598eb878b9bb3a924fd61bfc1142b26571979395",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754338613,
      "headline": "Vertex: Q2 Earnings Snapshot",
      "id": 136205910,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The Boston-based company said it had net income of $3.99 per share. Earnings, adjusted for one-time gains and costs, were $4.52 per share. The results beat Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=a0e2ef697c5b5d8e2f6fcddc598eb878b9bb3a924fd61bfc1142b26571979395"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results",
    "summary": "-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth- -Clinical trial ongoing for CTX310™, targeting ANGPTL3, with preliminary data showing dose-dependent reductions of up to 82% in triglycerides (TG) and 86% in low-density lipoprotein (LDL), and a well-tolerated safety profile; data presentation anticipated at a medical mee",
    "url": "https://finnhub.io/api/news?id=3b96aa8d6529f675d48c7ba6413405edd1202a0c0507b3b1ef7f8755f9d0d664",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754338500,
      "headline": "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results",
      "id": 136205911,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth- -Clinical trial ongoing for CTX310™, targeting ANGPTL3, with preliminary data showing dose-dependent reductions of up to 82% in triglycerides (TG) and 86% in low-density lipoprotein (LDL), and a well-tolerated safety profile; data presentation anticipated at a medical mee",
      "url": "https://finnhub.io/api/news?id=3b96aa8d6529f675d48c7ba6413405edd1202a0c0507b3b1ef7f8755f9d0d664"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ETCompany ParticipantsCharles F.",
    "url": "https://finnhub.io/api/news?id=b9bf5f3aa7ab419c9b28f17e465455facff1187785d1a57abdd335b82318b14a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754338420,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript",
      "id": 136204002,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ETCompany ParticipantsCharles F.",
      "url": "https://finnhub.io/api/news?id=b9bf5f3aa7ab419c9b28f17e465455facff1187785d1a57abdd335b82318b14a"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated 2025 Q2 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q2 earnings call.",
    "url": "https://finnhub.io/api/news?id=0af96dec6f199dfd0b854ec92a4d20462c372014406052d8727f40f24a65939c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754338346,
      "headline": "Vertex Pharmaceuticals Incorporated 2025 Q2 - Results - Earnings Call Presentation",
      "id": 136204003,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2025 Q2 earnings call.",
      "url": "https://finnhub.io/api/news?id=0af96dec6f199dfd0b854ec92a4d20462c372014406052d8727f40f24a65939c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain",
    "summary": "BOSTON, August 04, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of th",
    "url": "https://finnhub.io/api/news?id=7102cc0e1c6d059c53ae71fbe5def69291bd40873bd49c924be3e8363622e701",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754337660,
      "headline": "Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain",
      "id": 136205659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, August 04, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of th",
      "url": "https://finnhub.io/api/news?id=7102cc0e1c6d059c53ae71fbe5def69291bd40873bd49c924be3e8363622e701"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Reports Second Quarter 2025 Financial Results",
    "summary": "BOSTON, August 04, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2025, and reiterated full year 2025 financial guidance.",
    "url": "https://finnhub.io/api/news?id=975929aa13baa647750a3eb88ac06d2cb0c01dcdd8e77651b220b12e4db0bb25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754337660,
      "headline": "Vertex Reports Second Quarter 2025 Financial Results",
      "id": 136205912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, August 04, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2025, and reiterated full year 2025 financial guidance.",
      "url": "https://finnhub.io/api/news?id=975929aa13baa647750a3eb88ac06d2cb0c01dcdd8e77651b220b12e4db0bb25"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",
    "summary": "Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",
    "url": "https://finnhub.io/api/news?id=c28a6b33f80e0f491de35081da91af34865bb8e950e781eb1fe337a63ebb657a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754337000,
      "headline": "Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",
      "id": 136234825,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl",
      "url": "https://finnhub.io/api/news?id=c28a6b33f80e0f491de35081da91af34865bb8e950e781eb1fe337a63ebb657a"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=61d71078dce7ff8db7fc4fccf044f75e60fe2dd50347764231c94e8f4baa1b65",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754325480,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 136253498,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=61d71078dce7ff8db7fc4fccf044f75e60fe2dd50347764231c94e8f4baa1b65"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb",
    "summary": "Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb",
    "url": "https://finnhub.io/api/news?id=fad7c4219abb6cf879bf30e1fec4841ade2064350268424121a49c06256b90e8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754325000,
      "headline": "Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb",
      "id": 136253499,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb",
      "url": "https://finnhub.io/api/news?id=fad7c4219abb6cf879bf30e1fec4841ade2064350268424121a49c06256b90e8"
    }
  }
]